Ilyang Pharmaceutical launches ‘Supect’ as a primary treatment of leukemia
‘Supect(generic name: radotinib),’ the Asia’s first leukemia treatment developed by Ilyang Pharmaceutical(CEO Dong-yeon Kim), will be launched as the ‘primary treatment’ on the 1st of February.
Supect, which has proceeded the change of the insurance benefit standard after acquiring approval as a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
